CA2477967C - Derives de la purine en tant qu'inhibiteurs de la kinase - Google Patents

Derives de la purine en tant qu'inhibiteurs de la kinase Download PDF

Info

Publication number
CA2477967C
CA2477967C CA2477967A CA2477967A CA2477967C CA 2477967 C CA2477967 C CA 2477967C CA 2477967 A CA2477967 A CA 2477967A CA 2477967 A CA2477967 A CA 2477967A CA 2477967 C CA2477967 C CA 2477967C
Authority
CA
Canada
Prior art keywords
indol
dihydro
diazepino
dioxo
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2477967A
Other languages
English (en)
Other versions
CA2477967A1 (fr
Inventor
Joshua Ryan Clayton
Clive Gideon Diefenbacher
Thomas Albert Engler
Kelly Wayne Furness
James Robert Henry
Sushant Malhotra
Angela Lynn Marquart
Johnathan Alexander Mclean
David Mendel
Timothy Paul Burkholder
Yihong Li
Jon Kevin Reel
Brian Raymond Berridge
Charles Edward Ruegg
John Morris Sullivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA2477967A1 publication Critical patent/CA2477967A1/fr
Application granted granted Critical
Publication of CA2477967C publication Critical patent/CA2477967C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

L'invention concerne des inhibiteurs de la kinase représentés par la formule I.
CA2477967A 2002-03-05 2003-03-04 Derives de la purine en tant qu'inhibiteurs de la kinase Expired - Fee Related CA2477967C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36224502P 2002-03-05 2002-03-05
US60/362,245 2002-03-05
PCT/US2003/005050 WO2003076442A1 (fr) 2002-03-05 2003-03-04 Derives de la purine en tant qu'inhibiteurs de la kinase

Publications (2)

Publication Number Publication Date
CA2477967A1 CA2477967A1 (fr) 2003-09-18
CA2477967C true CA2477967C (fr) 2010-08-10

Family

ID=27805149

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2477967A Expired - Fee Related CA2477967C (fr) 2002-03-05 2003-03-04 Derives de la purine en tant qu'inhibiteurs de la kinase

Country Status (16)

Country Link
US (4) US7491716B2 (fr)
EP (1) EP1483265B1 (fr)
JP (1) JP4414232B2 (fr)
KR (1) KR100974770B1 (fr)
CN (1) CN1312154C (fr)
AT (1) ATE346070T1 (fr)
AU (1) AU2003215325B8 (fr)
BR (1) BR0308243B1 (fr)
CA (1) CA2477967C (fr)
CY (1) CY1109006T1 (fr)
DE (1) DE60309848T2 (fr)
DK (1) DK1483265T3 (fr)
ES (1) ES2276048T3 (fr)
IL (2) IL163781A0 (fr)
PT (1) PT1483265E (fr)
WO (1) WO2003076442A1 (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2477984A1 (fr) * 2002-03-08 2003-09-18 Pamela Ann Albaugh Inhibiteurs de kinases
GB0212049D0 (en) * 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
DK1846406T5 (da) 2005-02-09 2011-10-31 Arqule Inc Maleimidderivater, farmaceutiske sammensætninger og fremgangsmåder til behandling af cancer
US20080207594A1 (en) * 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
ATE542535T1 (de) * 2005-05-04 2012-02-15 Develogen Ag Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
TW200800203A (en) 2006-03-08 2008-01-01 Astrazeneca Ab New use
WO2007106537A2 (fr) * 2006-03-13 2007-09-20 Activx Biosciences, Inc. Aminoquinolones utilisées comme inhibiteurs de la gsk-3
EP1845098A1 (fr) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, leur procédés de préparation et leur utilisation comme ligands du recepteur GABA
WO2007134136A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN101302216B (zh) * 2007-05-11 2011-08-10 上海睿智化学研究有限公司 稠环吲哚类化合物的制备方法
CN101801937A (zh) 2007-06-22 2010-08-11 艾科尔公司 喹唑啉酮化合物及其使用方法
JP5490688B2 (ja) 2007-06-22 2014-05-14 アークル インコーポレイテッド 癌の治療のためのインドリルピロリジン
CA2690799C (fr) 2007-06-22 2015-06-16 Arqule, Inc. Derives de pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine et thiosuccinimide, compositions et procedes pour le traitement d'un cancer
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
ES2524266T3 (es) * 2008-07-08 2014-12-04 Incyte Corporation 1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa
WO2010003624A2 (fr) 2008-07-09 2010-01-14 Sanofi-Aventis Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
MX2011010937A (es) * 2009-04-14 2011-11-02 Lilly Co Eli Derivado benzodiazepina para el tratamiento de neoplasma hermatopoyetico y leucemia.
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
CA2778949C (fr) 2009-10-30 2018-02-27 Janssen Pharmaceutica Nv Derives d'imidazo[1,2-b]pyridazine et leur utilisation comme inhibiteurs de pde10
US8563567B2 (en) 2009-12-30 2013-10-22 Arqule, Inc. Substituted heterocyclic compounds
US8198285B2 (en) 2010-01-19 2012-06-12 Astrazeneca Ab Pyrazine derivatives
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2655372B8 (fr) * 2010-12-23 2016-09-07 ArQule, Inc. Compositions de pyrroloquinoléinyl-pyrrolidine-2,5-dione et procédés pour préparer et utiliser ceux-ci
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120058A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120050A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, médicaments contenant ces composés et leur utilisation
EP2683703B1 (fr) 2011-03-08 2015-05-27 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
RU2657540C2 (ru) 2012-06-26 2018-06-14 Янссен Фармацевтика Нв Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств
EP2869822B1 (fr) 2012-07-09 2016-09-14 Janssen Pharmaceutica, N.V. Inhibiteurs de l'enzyme phosphodiestérase 10
WO2014098000A1 (fr) * 2012-12-17 2014-06-26 Daiichi Sankyo Company, Limited Procédé de préparation d'un hétérocycle tricyclique
TW201506010A (zh) 2013-06-26 2015-02-16 Daiichi Sankyo Co Ltd 三環雜環化合物之製造方法
EP2818471A1 (fr) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composés bicycliques d'azote en tant qu'inhibiteurs de Scyl1 et Grk5
MX390321B (es) 2016-12-30 2025-03-20 Frequency Therapeutics Inc Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
US20200113913A1 (en) 2017-04-11 2020-04-16 Frequency Therapeutics, Inc. Methods for hair follicle stem cell proliferation
WO2019126686A1 (fr) * 2017-12-21 2019-06-27 Frequency Therapeutics, Inc. Composés 1,2-dihydro-3h-pyrazol-3-one et leurs procédés d'utilisation
US10526343B2 (en) 2018-03-26 2020-01-07 University Of Sharjah Heterocyclic systems and pharmaceutical applications thereof
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
AU2019318209B2 (en) 2018-08-10 2025-09-25 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
US20200121681A1 (en) 2018-10-17 2020-04-23 Frequency Therapeutics, Inc. Methods for hair follicle stem cell proliferation
CN113164508B (zh) 2018-12-19 2025-07-08 达萨玛治疗公司 与神经保护剂组合的sarm1抑制剂
EP3920885A1 (fr) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Composés d'acide valproïque et agonistes wnt pour le traitement de troubles de l'oreille
CN112390794B (zh) * 2019-08-19 2023-05-26 鲁南制药集团股份有限公司 一种米诺膦酸关键中间体的制备方法
CN115925622B (zh) * 2023-02-10 2025-04-22 山西永津集团有限公司 一种3-氰基吡啶-2-基氨基甲酸叔丁酯的合成方法
CN115974850B (zh) * 2023-02-16 2024-08-06 中国药科大学 一类作为akr1c3抑制剂的化合物及其制备方法与用途
US20260115199A1 (en) 2024-10-31 2026-04-30 Hoffmann-La Roche Inc. Tricyclic compounds for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK75289A3 (en) 1988-02-10 1998-05-06 Hoffmann La Roche Substituted pyrroles, their use for producing a drug, and the drug on their base
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
WO1998016528A1 (fr) * 1996-10-11 1998-04-23 Chiron Corporation Inhibiteurs puriques de glycogene synthase kinase 3 (gsk3)
GB9828640D0 (en) 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
DE60010934T2 (de) 1999-12-16 2005-05-19 Eli Lilly And Co., Indianapolis Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
US6867198B2 (en) 1999-12-16 2005-03-15 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
IL153851A0 (en) 2000-07-27 2003-07-31 Hoffmann La Roche 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
DE60112611T2 (de) 2000-12-08 2006-06-14 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
KR20040016828A (ko) 2000-12-08 2004-02-25 오르토-맥네일 파마슈티칼, 인코퍼레이티드 키나제 저해제로서 인다졸릴-치환된 피롤린 화합물

Also Published As

Publication number Publication date
AU2003215325B8 (en) 2008-10-09
PT1483265E (pt) 2007-01-31
AU2003215325B2 (en) 2008-09-18
BR0308243B1 (pt) 2014-08-26
US8058425B2 (en) 2011-11-15
US20090105229A1 (en) 2009-04-23
EP1483265B1 (fr) 2006-11-22
DE60309848T2 (de) 2007-05-16
US7491716B2 (en) 2009-02-17
US8022065B2 (en) 2011-09-20
ES2276048T3 (es) 2007-06-16
WO2003076442A1 (fr) 2003-09-18
CN1312154C (zh) 2007-04-25
DE60309848D1 (de) 2007-01-04
IL163781A0 (en) 2005-12-18
CA2477967A1 (fr) 2003-09-18
US20110207721A1 (en) 2011-08-25
US20050090483A1 (en) 2005-04-28
ATE346070T1 (de) 2006-12-15
JP4414232B2 (ja) 2010-02-10
BR0308243A (pt) 2005-01-11
IL163781A (en) 2010-04-15
JP2005526072A (ja) 2005-09-02
DK1483265T3 (da) 2007-03-19
CY1109006T1 (el) 2014-07-02
US20110294792A1 (en) 2011-12-01
EP1483265A1 (fr) 2004-12-08
CN1639165A (zh) 2005-07-13
AU2003215325A1 (en) 2003-09-22
KR100974770B1 (ko) 2010-08-06
KR20040087338A (ko) 2004-10-13

Similar Documents

Publication Publication Date Title
AU2003215325B2 (en) Purine derivatives as kinase inhibitors
AU2007209689B2 (en) Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors
JP5156150B2 (ja) 新規な多環式化合物およびそれらの使用
CN111867590B (zh) Atr激酶的杂环抑制剂
CZ301751B6 (cs) Bicyklický pyrrolový derivát, farmaceutická kompozice obsahující tento derivát, tato kompozice pro použití pri lécení a použití uvedeného derivátu pri výrobe léciva
AU2023501A (en) Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same
EP4288431A1 (fr) Inhibiteurs de shp2 azabicycliques
CN117836297A (zh) (s)-1-(5-((吡啶-3-基)硫代)吡嗪-2-基)-4'h,6'h-螺[哌啶-4,5'-吡咯并[1,2-b]吡唑]-4'-胺衍生物和类似化合物作为shp2抑制剂用于例如癌症的治疗
AU2006273692B2 (en) 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
CN118139862A (zh) 含氮杂环类化合物及其医药用途
TW202532070A (zh) 四並環類衍生物抑制劑、其製備方法和應用
DE60010934T2 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
WO2024109660A1 (fr) Inhibiteurs de cdk

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180305